Pharma M&A versus alliances and its underlying value drivers

Table Of Contents

• Cover
• Title
• Copyright
• About the author(s)/editor(s)
• About the book
• This eBook can be cited
• Content
• Table Index
• Graph Index
• A. Introduction
• I. The Pharmaceutical Industry and Its Paradigm Shift
• I.1 History
• I.2 Market Analysis
• I.2.1 Market Definition
• I.2.2 Market Size and Market Growth
• I.2.3 Big Pharma
• I.2.4 Geographic Segmentation
• I.2.5 Therapeutic Segmentation
• I.2.6 Blockbusters
• I.3 Innovation and Innovation Crisis
• I.3.1 R&D Productivity
• I.3.2 R&D Process
• I.3.3 R&D Pipeline
• I.4 Patent Protection and Patent Cliff
• I.5 Generics
• I.6 Biotechnology
• I.7 Pricing, Funding and Governmental Austerity Measures
• I.8 Restructuring Programs
• I.9 Summary
• II. The Pharmaceutical Industry and Mergers & Acquisitions
• II.1 M&A Deal Rationales
• II.1.1 Scale & Synergy Deals
• II.1.2 Innovation Deals
• II.1.3 Pharmerging Market Deals
• II.1.4 Diversification Deals
• II.2 Status of Consolidation
• II.3 M&A Activity Development
• II.4 Top Pharmaceutical M&A Transactions
• II.5 Summary
• III. Value Creation in Pharmaceutical M&A and its underlying Value Drivers
• III.1 Literature Review and Literature Contribution
• III.2 Data Sample
• III.3 Deal Statistics
• III.4 Research Methodology
• III.5 Acquirers’ Wealth Effects
• III.6 Univariate Subsample Analyses of M&A Value Drivers
• III.6.1 Target’s Business Nature
• III.6.2 Geographical Focus
• III.6.3 Pharmaceutical Merger Waves
• III.6.4 Relative Transaction Size
• III.6.5 Method of Payment
• III.6.6 Target’s R&D Intensity
• III.6.7 Strategic Alliances Pre-Merger
• III.6.8 M&A Experience
• III.6.9 Relative Price Level
• III.6.10 Target’s Financials
• III.7 Multivariate Analysis of M&A Value Drivers
• III.8 Conclusions and Recommendations
• IV. The Pharmaceutical Industry and Alliances
• IV.1 Strategic Alliances
• IV.2 Pharmaceutical In-Licensing
• IV.3 In-Licensing Activity Development
• IV.4 Top In-Licensing Deals
• IV.5 Summary
• V. Value Creation in Pharmaceutical In-licensings and its underlying Value Drivers
• V.1 Literature Review and Literature Contribution
• V.2 Data Sample
• V.3 Deal Statistics
• V.4 Licensee’s Wealth Effects
• V.5 Univariate Subsample Analyses of In-licensing Value Drivers136
• V.5.1 National and cross-border Partnerships
• V.5.2 M&A Waves
• V.5.3 Stage of Drug Candidate
• V.5.4 Targeted Therapeutical Area
• V.5.5 Financial deal components
• V.5.6 US Co-commercialization Rights
• V.5.7 Prior-licensing Alliances
• V.5.8 Licensees’ experience
• V.6 Multivariate Analysis of In-licensing Value Drivers
• V.7 Conclusions and Recommendations
• VI. M&A versus In-licensing
• VII. Conclusions and Future Research
• B. References
• C. List of Abbreviations